NAVB Profile
Navidea Biopharmaceuticals, Inc., a leading biopharmaceutical firm headquartered in Dublin, Ohio, specializes in the advancement and commercialization of precision immunodiagnostic agents and immunotherapeutics. Established in 1983, the company operates through two distinct segments: Diagnostic Substances and Therapeutic Development Programs, each focused on leveraging its innovative Manocept platform.
The Manocept platform targets the CD206 mannose receptor found on activated macrophages, enabling a spectrum of diagnostic applications such as single photon emission computed tomography (SPECT), positron emission tomography (PET), gamma-scanning, and optical-fluorescence detection. Additionally, this platform facilitates the delivery of therapeutic compounds that specifically target macrophages, addressing immune- and inflammation-related diseases.
Navidea Biopharmaceuticals has made significant strides in clinical development, with NAV3-31 having completed Phase IIb trials to assess imaging repeatability and stability. This agent aims to evaluate Tc99m tilmanocept imaging for anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA). Other notable developments include NAV3-35 and NAV3-33, currently in Phase IIb and Phase III trials respectively, for imaging and therapeutic applications in RA-involved joints.
Formerly known as Neoprobe Corporation, the company rebranded as Navidea Biopharmaceuticals, Inc. in January 2012 to better reflect its expanded focus and innovative approach in the biopharmaceutical sector. With ongoing research into Tc99m tilmanocept for diverse applications including cardiovascular diseases, Kaposi's sarcoma, tuberculosis, and other immunotherapeutic uses, Navidea Biopharmaceuticals continues to pioneer advancements aimed at improving diagnostic precision and therapeutic outcomes globally.
|
